Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same
Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2θ±0.2°) of 12.8°, 18.1° and/or 23.5° in a powder X-ray diffraction are excellent in stability against light, therefore are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as constipation.
1. A crystal of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a diffraction peak at a diffraction angle (2θ±0.2°) of 12.8°, 18.1° and/or 23.5° in a powder X-ray diffraction.
2. A crystal of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one having a peak at a chemical shift of approximately 113.1 ppm and/or approximately 140.8 ppm in a 13 C solid state NMR spectrum.
3. A process for preparing a crystal according to claim 1 , characterized by that 5-[2-amino-4-(2-furyl;)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one is heated and dissolved in a solvent and then crystallized by gradual cooling.
4. A process for preparing a crystal according to claim 2 , characterized by that 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1H)-one is heated and dissolved in a solvent and then crystallized by gradual cooling.